Prognostic value of HMGN family expression in acute myeloid leukemia

• Published in: Future oncology (London, England) Vol. 17; no. 5; pp. 541 - 548
• Main Authors: Cui, Wei, Liu, Yuna, Tan, Yanan, Peng, Xingyue, Cui, Longzhen, Cheng, Zhiheng, Dai, Yifeng, Fu, Lin, Zeng, Tiansheng, Liu, Yan
• Format: Journal Article
• Language: English
• Published: England 01.02.2021
• Subjects: HMGN5; acute myeloid leukemia; HMGN2; prognosis; heterogeneity
• ISSN: 1479-6694; 1744-8301
• DOI: 10.2217/fon-2020-0555

The objective of this work was to investigate the prognostic role of the family in acute myeloid leukemia (AML). A total of 155 AML patients with expression data from the Cancer Genome Atlas database were enrolled in this study. In the chemotherapy-only group, patients with high expression had significantly longer event-free survival (EFS) and overall survival (OS) than those with low expression (all p < 0.05), whereas high expressers had shorter EFS and OS than the low expressers (all p < 0.05). Multivariate analysis identified that high expression was an independent favorable prognostic factor for patients who only received chemotherapy (all p < 0.05).  family expression had no impact on EFS and OS in AML patients receiving allogeneic hematopoietic stem cell transplantation. High expression is a potential prognostic indicator for AML.